Back to Results

ADMA Biologics Inc (ADMA)

ADMA Biologics Inc. is a NASDAQ-listed common stock company in the healthcare sector focused on biotechnology. The company develops, manufactures, and commercializes specialty plasma-derived biologics used in the treatment of immune deficiencies and infectious diseases in the United States and international markets. Its operations are organized into ADMA BioManufacturing and Plasma Collection Centers, supporting both production and plasma sourcing activities.

ADMA’s marketed products include BIVIGAM, an intravenous immune globulin for primary humoral immunodeficiency; ASCENIV, another IVIG therapy for primary humoral immunodeficiency; and Nabi-HB, a human polyclonal antibody product used in connection with acute exposure to blood containing hepatitis B surface antigen and related exposures. The company also maintains a pipeline of plasma-derived therapeutics, including programs related to the treatment and prevention of S. pneumonia infection for an immunoglobulin. ADMA Biologics sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. The company was incorporated in 2004 and is headquartered in Ramsey, New Jersey.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-ADMA
$12.04
22.7% Upside
Undervalued
$17
73.3% Upside
Bargain
Great
0.0%
November 11, 2026
12.6x
5.2x
4.2x
2.197 B
2.197 B
8.7%
98.1%
7.1
68.9%
Valuation • Fair Value

ADMA Biologics Inc (NASDAQ-ADMA) Fair Value by Valuation Model

Review the available estimates for ADMA Biologics Inc (NASDAQ-ADMA), including DCF Fair Value, Ben Graham Formula Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$12.04

Estimated upside of 22.7% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$15.17

Discounted cash flow valuation reference.

Ben Graham Formula Value

$8.37

Classic Ben Graham valuation formula reference.

Comps Fair Value

$10.99

Comparable-company valuation reference.

Analyst Price Target

$17

Analysts imply upside of 73.3%.

How to read these valuation models

Use the 6 available valuation references for ADMA Biologics Inc (NASDAQ-ADMA) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for ADMA Biologics Inc (NASDAQ-ADMA)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

512.3 M

Current operating scale indicator.

Revenue Forecast

532.4 M

Forward revenue estimate.

EBITDA

224.2 M

Current operating profitability reference.

EBITDA Forecast

277.4 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review ADMA Biologics Inc (NASDAQ-ADMA) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for ADMA Biologics Inc (NASDAQ-ADMA)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-2.39

No elevated caution signal from this screen.

Altman Z-Score

7.1

Relatively strong balance-sheet zone.

FCF / Net Income

68.9%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for ADMA Biologics Inc (NASDAQ-ADMA). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for ADMA Biologics Inc (NASDAQ-ADMA)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 11, 2026

Days to Earnings

50

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for ADMA Biologics Inc (NASDAQ-ADMA), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

ADMA Biologics Inc (NASDAQ-ADMA) Stock Forecast & Technical Outlook

Review ADMA Biologics Inc (NASDAQ-ADMA) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for ADMA Biologics Inc (NASDAQ-ADMA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for ADMA Biologics Inc (NASDAQ-ADMA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for ADMA Biologics Inc (NASDAQ-ADMA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for ADMA Biologics Inc (NASDAQ-ADMA) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for ADMA Biologics Inc (NASDAQ-ADMA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for ADMA Biologics Inc (NASDAQ-ADMA)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, ADMA Biologics Inc (NASDAQ-ADMA) has a Buy consensus, with 2 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 1
Sell 0
FAQ • Fast Investor Answers

ADMA Biologics Inc (NASDAQ-ADMA) Stock FAQ

Data-supported answers about ADMA Biologics Inc (NASDAQ-ADMA), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$12.04
Estimated upside 22.7%
Valuation Rating
Undervalued
Estimated upside of 22.7%
Analyst Target
$17
Implied upside 73.3%
Financial Health
Great
Current financial-health read

The current fair value estimate for ADMA Biologics Inc (NASDAQ-ADMA) is $12.04. This implies an estimated upside of 22.7% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 22.7% versus the current market price.

The available analyst price target for ADMA Biologics Inc (NASDAQ-ADMA) is $17. The analyst target implies estimated upside of 73.3%.

The current financial health read for ADMA Biologics Inc (NASDAQ-ADMA) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for ADMA Biologics Inc (NASDAQ-ADMA) is November 11, 2026.

The latest available data indicates no current dividend yield for ADMA Biologics Inc (NASDAQ-ADMA).

The current P/E ratio listed for ADMA Biologics Inc (NASDAQ-ADMA) is 12.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for ADMA Biologics Inc is 2.197 B.

The current enterprise value listed for ADMA Biologics Inc is 2.197 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for ADMA Biologics Inc is NASDAQ-ADMA, and the stock is listed on NASDAQ.

ADMA Biologics Inc (NASDAQ-ADMA) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for ADMA Biologics Inc is 8.7%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for ADMA Biologics Inc is 98.1%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B